IP Library Granted Patent US 8,900,583
Granted Patent B2
US 8,900,583 · App. 13/848,044 · Granted Dec 2, 2014

Methods for treatment of brain injury utilizing biologics

Inventor: Edward Lewis Tobinick (Boca Raton, FL)
Assignee: TACT IP LLC
A61K39/3955C07K14/7151C07K16/241A61K9/0085A61K2039/505C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,900,583
App. No.
13/848,044
Granted
Dec 2, 2014
Kind
B2
Abstract

A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included.

Claims (15)

1. A method for treating spasticity associated with a chronic brain injury, comprising: administering to a perispinal area of a human who has suffered a brain injury at least 3 months previously and is experiencing spasticity, a therapeutically effective amount of etanercept for treating spasticity.

2. The method of claim 1 , wherein said human suffered a brain injury at least 24 months previously.

3. The method of claim 2 , wherein the brain injury was a stroke.

4. The method of claim 1 , wherein said human suffered a brain injury at least 36 months previously.

5. The method of claim 4 , wherein the brain injury was a stroke.

6. The method of claim 1 , wherein the etanercept is administered without direct intrathecal injection.

7. The method of claim 1 , wherein the etanercept is administered external to ligamentum flavum.

8. The method of claim 1 , wherein said human also has a condition selected from the group consisting of a mood disorder, sleep disorder, cognitive disorder, aphasia, hemiplegia, sensory deficit, post-traumatic stress disorder and pain.

9. The method of claim 1 , wherein said human is placed in a Trendelenburg position after administering etanercept.

10. The method of claim 1 , wherein etanercept is administered epidurally.

11. The method of claim 1 , wherein the brain injury was a stroke.

12. The method of claim 1 , wherein the chronic brain injury resulted from an acute brain injury.

13. The method of claim 1 , wherein an initial dose is followed by one subsequent dose.

14. The method of claim 1 , wherein an initial dose is followed by two subsequent doses.

15. The method of claim 1 , wherein the etanercept isa dimeric fusion protein consisting of two soluble TNF receptors fused to a Fc portion of an immunoglobulin molecule.

Assignments (3)
ADDRESS CHANGE Recorded Oct 4, 2017
From: TACT IP, LLC
To: TACT IP, LLC
Reel/Frame 044127/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2013
From: TOBINICK, EDWARD LEWIS, MD
To: TACT IP LLC
Reel/Frame 030055/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2013
From: TOBINICK, EDWARD LEWIS
To: TACT IP LLC
Reel/Frame 030062/0340 →
Continuity (4)
Provisional Application 61409012 · Nov 1, 2010
Provisional Application 61413440 · Nov 13, 2010
Provisional Application 61413444 · Nov 14, 2010
Related Publication 20130224197A1 · Aug 29, 2013